European Journal of Pharmaceutics and Biopharmaceutics,
Год журнала:
2024,
Номер
203, С. 114446 - 114446
Опубликована: Авг. 8, 2024
Efficient
tumour
treatment
is
hampered
by
the
poor
selectivity
of
anticancer
drugs,
resulting
in
scarce
accumulation
and
undesired
off-target
effects.
Nano-sized
drug-delivery
systems
form
nanoparticles
(NPs)
have
been
proposed
to
improve
drug
distribution
solid
tumours,
virtue
their
ability
passive
active
targeting.
Despite
these
advantages,
literature
studies
indicated
that
less
than
1%
administered
NPs
can
successfully
reach
mass,
highlighting
necessity
for
more
efficient
transporters
cancer
treatment.
Living
cells,
such
as
blood
circulating
immune
platelets,
stem
are
often
found
an
infiltrating
component
most
because
naturally
circumvent
recognition,
bypass
biological
barriers,
inaccessible
tissues
through
innate
tropism
motility.
Therefore,
tumour-homing
cells
be
harnessed
design
living
cell
carriers
able
transport
drugs
tumours.
Albeit
promising,
this
approach
still
its
beginnings
suffers
from
difficult
scalability,
high
cost,
reproducibility.
In
review,
we
present
overview
common
NPs,
discuss
how
different
types
interact
with
barriers
deliver
cargoes
various
natures
Finally,
analyse
techniques
used
load
or
advantages
disadvantages.
Pharmacological Research,
Год журнала:
2024,
Номер
206, С. 107308 - 107308
Опубликована: Июль 15, 2024
Glioma
is
the
most
common
intracranial
malignant
tumor,
with
severe
difficulty
in
treatment
and
a
low
patient
survival
rate.
Due
to
heterogeneity
invasiveness
of
tumors,
lack
personalized
clinical
design,
physiological
barriers,
it
often
difficult
accurately
distinguish
gliomas,
which
dramatically
affects
subsequent
diagnosis,
imaging
treatment,
prognosis.
Fortunately,
nano-delivery
systems
have
demonstrated
unprecedented
capabilities
diagnosing
treating
gliomas
recent
years.
They
been
modified
surface
efficiently
traverse
BBB/BBTB,
target
lesion
sites,
intelligently
release
therapeutic
or
contrast
agents,
thereby
achieving
precise
treatment.
In
this
review,
we
focus
on
systems.
Firstly,
provide
an
overview
standard
emerging
diagnostic
technologies
for
glioma
practice.
After
induction
analysis,
summarizing
delivery
methods
drug
systems,
design
nanoparticles,
their
new
advances
Finally,
discussed
prospects
potential
challenges
drug-delivery
glioma.
Hepatocellular
carcinoma
(HCC)
is
one
of
the
most
prevalent
cancers,
characterized
by
high
morbidity
and
mortality
rates.
Recently,
immunotherapy
has
emerged
as
a
crucial
treatment
modality
for
HCC,
following
surgery,
locoregional
therapies,
targeted
therapies.
This
approach
harnesses
body's
immune
system
to
target
eliminate
cancer
cells,
potentially
resulting
in
durable
antitumor
responses.
However,
acquired
resistance
tumor
immunosuppressive
microenvironment
(TIME)
significantly
hinder
its
clinical
application.
advancements
nanotechnology,
coupled
with
deeper
understanding
biology
nano-biological
interactions,
have
led
development
various
nanoparticles
aimed
at
enhancing
therapeutic
efficacy
through
specific
targeting
tissues.
These
increase
accumulation
immunotherapeutic
drugs
within
microenvironment,
thereby
transforming
TIME.
In
this
review,
we
provide
concise
overview
fundamental
principles
governing
TIME
landscape
HCC
discuss
rationale
applications
context.
Additionally,
highlight
existing
challenges
potential
opportunities
translation
nanomedicines.
PeerJ,
Год журнала:
2025,
Номер
13, С. e19199 - e19199
Опубликована: Апрель 8, 2025
Fungal
infections
present
an
increasing
global
health
challenge,
with
a
substantial
annual
mortality
rate
of
1.6
million
deaths
each
year
in
certain
situations.
The
emergence
antifungal
resistance
has
further
complicated
treatment
strategies,
underscoring
the
urgent
need
for
novel
therapeutic
approaches.
This
review
explores
recent
advances
nanoparticle-based
therapies
targeting
fungal
infections,
emphasizing
their
unique
potential
to
enhance
drug
solubility,
bioavailability,
and
targeted
delivery.
Nanoparticles
offer
ability
penetrate
biological
barriers,
improve
stability,
act
as
direct
agents
by
disrupting
cell
walls
generating
reactive
oxygen
species.
Despite
promising
applications,
challenges
such
toxicity,
scalability
production,
controlled
release
remain.
Future
research
should
focus
on
optimizing
nanoparticle
properties,
evaluating
long-term
safety
profiles,
developing
environmentally
sustainable
synthesis
methods,
exploring
synergistic
approaches
existing
drugs.
Nanotechnology
offers
transformative
opportunity
management
diseases,
paving
way
more
effective
treatments.
Regenerative Biomaterials,
Год журнала:
2024,
Номер
12
Опубликована: Ноя. 20, 2024
Abstract
Low
tumor
enrichment
remains
a
serious
and
urgent
problem
for
drug
delivery
in
cancer
therapy.
Accurate
targeting
of
sites
is
still
critical
aim
Though
there
have
been
variety
strategies
to
improve
the
enrichment,
biological
barriers
cause
most
delivered
guests
fail
or
be
excreted
before
they
work.
Recently,
cell
membrane-based
systems
attracted
huge
amount
attention
due
their
advantages
such
as
easy
access,
good
biocompatibility
immune
escape,
which
contribute
biomimetic
structures
specific
surface
proteins.
Furthermore,
are
referred
homologous-targeting
function
exhibit
significantly
high
adhesion
internalization
homologous-type
cells
even
though
exact
mechanism
not
entirely
revealed.
Here,
we
summarize
sources
characterizations
membrane
systems,
including
reconstructed
single
hybrid
nano-/microcarriers,
well
engineered
cells.
Additionally,
advanced
applications
these
therapy
categorized
summarized
according
components
membranes.
The
potential
factors
related
homologous
also
discussed.
By
discussing
applications,
challenges
opportunities,
expect
far-reaching
development
preclinic
clinics.
Advanced Healthcare Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 15, 2025
Immune
cells
show
enormous
potential
for
targeted
nanoparticle
delivery
due
to
their
intrinsic
tumor-homing
skills.
However,
the
immune
can
internalize
nanoparticles,
leading
cellular
functional
impairments,
degradation
of
and
delayed
release
drugs
from
cells.
To
address
these
issues,
this
study
introduces
an
approach
synthesis
freshly
derived
neutrophils
(NUs)-based
nanocarriers
system
where
NUs
are
surfaced
by
dialdehyde
alginate-coated
self-assembled
micelles
loaded
with
mitoxantrone
(MIT)
indocyanine
green
(ICG)
(i.e.,
dA(MI@IPM)s)
stimuli-responsive
tumor-targeted
therapy.
Here,
dA(MI@IPM)s
not
internalized
NUs,
but
they
anchored
on
membrane
via
distearoylphosphatidylethanolamine-polyethylene
glycol-polyethylenimine
anchors.
Owing
natural
recruitment
ability
tumor
microenvironment,
NUs-anchored
accumulation
is
higher
at
site
than
free
dA(MI@IPM)s,
readily
detach
get
in
The
disassembles
inside
cancer
upon
near-infrared
irradiation
photosensitizing
effect
ICG,
releasing
MIT
significantly
inhibiting
growth.
This
simple
fast
prepare,
opening
up
exciting
possibilities
personalized
treatment
using
patient's
autologous
NUs.
Many
poly(amine-
co
-ester)
(PACE)
nanoparticles,
drug
delivery
vehicles
for
nucleic
acid
and
small
molecule
cargoes,
accumulate
in
the
liver
spleen
following
intravenous
administration,
limiting
to
nonhepatosplenic
tissues.
Red
blood
cell
(RBC)
hitchhiking,
a
strategy
which
nanoparticles
are
nonspecifically
adsorbed
RBCs
prior
has
been
used
modulate
nanoparticle
biodistribution,
enabling
enrichment
organs
immediately
downstream
from
site
of
vascular
infusion.
We
find
that
scarcely
investigated
cellular
determinants—namely,
storage
duration,
membrane
stiffness,
membrane-bound
sialic
quantity—substantially
affect
PACE
adsorption
efficiency.
Following
development
an
optimized
protocol,
RBC
hitchhiking
was
shown
enhance
cargo
pulmonary
tissue
while
also
increasing
exposure
other
assayed
organs.
These
findings
inform
future
study
design,
implicate
variables
as
potential
obstacles
or
boons
clinical
translation,
demonstrate
acids
using
this
with
platform.
